Generated by AI
Belite Bio, Inc. ADR is a clinical-stage biopharmaceutical company focused on developing oral therapies for degenerative retinal diseases and selected metabolic disorders. Its lead candidate, Tinlarebant, is being studied for eye conditions such as Stargardt disease type 1 and geographic atrophy, with an emphasis on preserving retinal health and slowing disease progression. The company also develops LBS-009, a preclinical oral therapy aimed at metabolic diseases including liver disorders, type 2 diabetes, and gout. Belite Bio, Inc. ADR operates in the biotechnology and pharmaceuticals sector, where it contributes to the advancement of targeted treatments for conditions with significant unmet medical needs. The company is based in San Diego, California, and focuses on drug discovery and development centered on small-molecule therapeutics.
Website12750 High Bluff Drive
San Diego, CA, 92130
United States
The latest articles about BLTE.
Summary of Sep 4's posts. Generated by AI.
No summary yet.
Summary of May 3's posts. Generated by AI.
Summary of Dec 1's posts. Generated by AI.
Investors talking about BLTE also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.